The UroLift® System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45* years or older (*50 years outside U.S.) and is the only BPH procedure that does not require cutting, heating or removal of prostate tissue.
Join our team of innovative, talented people who are on a mission to empower healthcare providers with BPH solutions that have the potential to improve the health and quality of life for millions of men, every year.
About Teleflex Interventional Urology:
The Teleflex Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive, and clinically effective devices that address unmet needs in the field of urology. Our focus is on improving the standard of care for patients with BPH.
Teleflex Incorporated is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose-driven innovation—a relentless pursuit of identifying unmet clinical needs—to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine, and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, visit Teleflex.com.
** Management estimate based on product sales and average units per procedure. For patient safety information, visit https://www.urolift.com/patient-safety.
-
Industry
-
Medical Equipment Manufacturing
-
Company size
-
10,001+ employees
-
Headquarters
-
Pleasanton, California
-
Type
-
Public Company
-
Founded
-
2004
-
Specialties
-
urology, BPH, medical device, enlarged prostate, and minimally invasive
